Table 2.
Standardized incidence ratios (SIRs) for carriers of monoallelic MUTYH mutations compared to the general population for cancers by sex
| Median age of diagnosis, year (min–max) | Observed number1 | Expected number | SIR (95%CI)2 | p | |
|---|---|---|---|---|---|
| Both sexes | |||||
| Colorectal cancer | 67 (24–89) | 10 | 4.93 | 2.04 (1.56–2.70) | <0.001 |
| Gastric cancer | 71 (48–85) | 3 | 0.85 | 3.24 (2.18–4.98) | <0.001 |
| Liver cancer | 62 (30–83) | 1 | 0.24 | 3.09 (1.07–12.25) | 0.07 |
| Pancreatic cancer | 65 (52–83) | 1 | 0.90 | 0.91 (0.34–3.25) | 0.87 |
| Brain cancer | 54 (35–84) | 1 | 0.74 | 1.66 (0.66–5.45) | 0.35 |
| Renal cancer | 65 (46–76) | 1 | 0.82 | 0.91 (0.36–2.97) | 0.86 |
| Lung cancer | 70 (26–82) | 4 | 5.57 | 0.71 (0.44–1.21) | 0.18 |
| Female | |||||
| Endometrial cancer | 60 (19–85) | 3 | 1.09 | 2.33 (1.18–5.08) | 0.02 |
| Breast cancer | 62 (35–83) | 7 | 5.63 | 1.27 (0.84–1.99) | 0.28 |
| Male | |||||
| Prostate cancer | 69 (39–87) | 3 | 4.17 | 0.69 (0.46–1.06) | 0.08 |
1
Observed number of cancers for monoallelic mutation carriers were calculated by multiplying the numbers of cancers by the probabilities of being a monoallelic carrier. Numbers were rounded to no decimal place.
2
Confidence interval based on with robust variance correction for familial correlation in risk